Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Hopes To Sow Future Deals With $50M Venture Fund

Executive Summary

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

You may also be interested in...

Shire Emphasizes The GI Space In Its Bid For Movetis

Only five years ago, Shire's specialty pharma business consisted of one product, Adderall XR, one market, the U.S., and one patient type - children. Multiple generics companies had filed ANDAs, however, and the company was looking to broaden its base

As Some VCs Run On Empty, Others Are Topping Off The Tank

New money is increasingly hard to come by for life sciences venture capital firms. Start-Up tracks VCs to determine which firms have older vintage funds and which have plenty of fresh capital to invest.

Boehringer Ingelheim Joins The Corporate Venture Party

In late March, Boehringer Ingelheim GMBH formally unveiled its $134 million corporate venture fund, a strategically-focused effort that will invest in areas believed to be important to the privately-held German pharma's future growth, including RNA silencing, stem cells, and next generation vaccine, protein, and antibody technologies.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts